Literature DB >> 8373405

Specific interaction between a novel enediyne chromophore and apoprotein in macromolecular antitumor antibiotic C-1027.

T Matsumoto1, Y Okuno, Y Sugiura.   

Abstract

The DNA cleavage experiments show that C-1027 chromophore is selectively incorporated into C-1027 apoprotein and is strongly protected by the apoprotein from loss of its DNA cleaving activity. Fluorescence and circular dichroism spectra reveal (1) important participation of tertiary structure of C-1027 apoprotein for the chromophore binding, (2) specific 1:1 binding of C-1027 chromophore to the apoprotein, and (3) significant interaction of the benzoxazine group in the chromophore-apoprotein complex. On the other hand, C-1027 apoprotein does not contribute to sequence-specificity DNA cleavage by C-1027 antibiotics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8373405     DOI: 10.1006/bbrc.1993.2096

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Pharmacokinetics of C-1027 in mice as determined by TCA-RA method.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Mao-Jin Zhou; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

2.  Tissue distribution and excretion of 125I-lidamycin in mice and rats.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

3.  Characterization of the SgcF epoxide hydrolase supporting an (R)-vicinal diol intermediate for enediyne antitumor antibiotic C-1027 biosynthesis.

Authors:  Shuangjun Lin; Geoffrey P Horsman; Yihua Chen; Wenli Li; Ben Shen
Journal:  J Am Chem Soc       Date:  2009-11-18       Impact factor: 15.419

4.  Biosynthesis of the enediyne antitumor antibiotic C-1027 involves a new branching point in chorismate metabolism.

Authors:  Steven G Van Lanen; Shuangjun Lin; Ben Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-08       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.